Circulating cytokines are associated with human islet graft function in type 1 diabetes

Clinical Immunology

Volumn 138, Issue 2, 2011, Pages 154-161

  Pfleger, Christian ^a   Schloot, Nanette C ^a,b   Brendel, Mathias D ^c   Burkart, Volker ^a   Hogenkamp, Viktor ^a   Bretzel, Reinhard G ^c   Jaeger, Clemens ^c   Eckhard, Michael ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Chemokines; Cytokines; Islet transplantation; Prediction; Regenerative therapy; Type 1 diabetes

Indexed keywords

AZATHIOPRINE; CHEMOKINE; CYCLOSPORIN; CYTOKINE; GLOBULIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MIGRATION INHIBITION FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ADULT; ALGA; ALLOGRAFT; ARTICLE; AUTOIMMUNITY; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; MACROPHAGE; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; REGRESSION ANALYSIS;

ADRENAL CORTEX HORMONES; ADULT; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CYCLOSPORINE; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID;

EID: 79251593795     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.10.008     Document Type: Article

References (38)

1. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
2. Roep B.O., Stobbe I., Duinkerken G., et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999, 48:484-490.
3. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J. Med. 2006, 355:1318-1330.
4. Naftanel M.A., Harlan D.M. Pancreatic islet transplantation. PLoS Med. 2004, 1:e58.
5. Emamaullee J.A., Shapiro A.M. Factors influencing the loss of beta-cell mass in islet transplantation. Cell Transplant. 2007, 16:1-8.
6. Velthuis J.H., Unger W.W., Abreu J.R., et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 2010, 59:1721-1730.
7. Velthuis J.H., Unger W.W., van der Slik A.R., et al. Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia 2009, 52:494-503.
8. Hilbrands R., Huurman V.A., Gillard P., et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009, 58:2267-2276.
9. Monti P., Scirpoli M., Maffi P., et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 2008, 118:1806-1814.
10. Rabinovitch A., Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 1998, 55:1139-1149.
11. Huurman V.A., Hilbrands R., Pinkse G.G., et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008, 3:e2435.
12. Rickels M.R., Kamoun M., Kearns J., et al. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J. Clin. Endocrinol. Metab. 2007, 92:2410-2414.
13. Roelen D.L., Huurman V.A., Hilbrands R., et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin. Exp. Immunol. 2009, 156:141-148.
14. Huurman V.A., Velthuis J.H., Hilbrands R., et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am. J. Transplant. 2009, 9:382-388.
15. Vantyghem M.C., Kerr-Conte J., Arnalsteen L., et al. Primary graft function, metabolic control, and graft survival after islet transplantation. Diab. Care 2009, 32:1473-1478.
16. Pfleger C., Kaas A., Hansen L., et al. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin. Immunol. 2008, 128:57-65.
17. Pfleger C., Mortensen H.B., Hansen L., et al. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008, 57:929-937.
18. Solomon M.F., Kuziel W.A., Mann D.A., et al. The role of chemokines and their receptors in the rejection of pig islet tissue xenografts. Xenotransplantation 2003, 10:164-177.
19. Kim Y.H., Lim D.G., Wee Y.M., et al. Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant. 2008, 17:609-618.
20. Lattmann T., Hein M., Horber S., et al. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling. Am. J. Transplant. 2005, 5:1042-1049.
21. Ogliari A.C., Caldara R., Socci C., et al. High levels of donor CCL2/MCP-1 predict graft-related complications and poor graft survival after kidney-pancreas transplantation. Am. J. Transplant. 2008, 8:1303-1311.
22. Bretzel R.G., Brandhorst D., Brandhorst H., et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J. Mol. Med. 1999, 77:140-143.
23. Bretzel R.G., Brendel M., Eckhard M., et al. Islet transplantation: present clinical situation and future aspects. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl 2):S384-S399.
24. Hering B.J., Bretzel R.G., Hopt U.T., et al. New protocol toward prevention of early human islet allograft failure. Transplant. Proc. 1994, 26:570-571.
25. Shimada A., Morimoto J., Kodama K., et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diab. Care 2001, 24:510-515.
26. Fourlanos S., Varney M.D., Tait B.D., et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diab. Care 2008, 31:1546-1549.
27. Hanifi-Moghaddam P., Schloot N.C., Kappler S., et al. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003, 52:1137-1142.
28. Asakura T., Ohkohchi N., Satomi S. Changes of serum cytokines associated with hepatic regeneration after living-related liver transplantation. Transplant. Proc. 2000, 32:2199-2203.
29. Conti F., Calmus Y., Rouer E., et al. Increased expression of interleukin-4 during liver allograft rejection. J. Hepatol. 1999, 30:935-943.
30. Conti F., Frappier J., Dharancy S., et al. Interleukin-15 production during liver allograft rejection in humans. Transplantation 2003, 76:210-216.
31. Cookson S., Doherty D.G., Todryk S., et al. Hepatic expression of IL-15 mRNA is associated with liver graft acceptance. Transpl. Immunol. 2003, 11:39-48.
32. Kita Y., Iwaki Y., Noguchi K., et al. Daily serum interleukin-6 monitoring in multiple organ transplantation with or without liver allografts. Transplant. Proc. 1996, 28:1229-1234.
33. Sankary H., Chong A., Frye E., et al. Daily determinations of serum lymphotoxin allows for accurate early diagnosis of hepatic allograft rejection. Transplant. Proc. 1993, 25:928-930.
34. Wieers G., Gras J., Bourdeaux C., et al. Monitoring tolerance after human liver transplantation. Transpl. Immunol. 2007, 17:83-93.
35. Benigni F., Atsumi T., Calandra T., et al. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J. Clin. Invest. 2000, 106:1291-1300.
36. Sakaue S., Nishihira J., Hirokawa J., et al. Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol. Med. 1999, 5:361-371.
37. Vozarova B., Stefan N., Hanson R., et al. Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistance. Diabetologia 2002, 45:1739-1741.
38. Herder C., Kolb H., Koenig W., et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4. Diab. Care 2006, 29:368-371.